This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AKAO Achaogen (AKAO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Achaogen Stock (NASDAQ:AKAO) Get Achaogen alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.11▼$0.1152-Week Range N/AVolumeN/AAverage Volume3.34 million shsMarket Capitalization$7.03 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Achaogen, Inc., a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved in the development of antibacterial candidate C-Scape, an orally-administered combination of clavulanate and ceftibuten, which targets serious bacterial infections due to expanded spectrum beta-lactamases producing enterobacteriaceae; and therapeutic antibody discovery program. The company has license and collaboration agreements with Thermo Fisher Scientific, Inc. to develop and commercialize an assay to support plazomicin; Crystal Biosciences, Inc. to discover monoclonal antibodies against multiple targets; Ionis Pharmaceuticals, Inc. for certain patents relating to aminoglycoside antibacterial compounds and related know-how to develop and commercialize certain novel aminoglycoside antibacterial compounds; and Hovione Limited to manufacture the active pharmaceutical ingredient for plazomicin. The company was incorporated in 2002 and is based in South San Francisco, California. Read More Receive AKAO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Achaogen and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AKAO Stock News HeadlinesTriangle execs armed with $70M seek next big idea in life sciencesNovember 19, 2024 | bizjournals.comHarry R Weller's Net WorthSeptember 13, 2024 | benzinga.comURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gold price (signaling fear), and escalating geopolitical risk. A sharp correction might happen tomorrow, and most investors will be caught off guard. Your portfolio is currently exposed.October 7 at 2:00 AM | StockEarnings (Ad)Ravi Viswanathan's Net WorthFebruary 21, 2024 | benzinga.comCOP28: Climate mums make themselves heard in halls of powerDecember 28, 2023 | bbc.comBAKAOQ Historical DataOctober 25, 2023 | investing.comSepterna Strengthens Leadership Team to Advance Novel Small Molecule GPCR Medicines - Yahoo FinanceJuly 28, 2022 | finance.yahoo.comAn N.J. medical expert warns of the rise of superbugs | Opinion - NJ.comJune 13, 2022 | nj.comNSee More Headlines AKAO Stock Analysis - Frequently Asked Questions How were Achaogen's earnings last quarter? Achaogen Inc (NASDAQ:AKAO) announced its quarterly earnings data on Monday, August, 6th. The biopharmaceutical company reported ($1.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.92) by $0.19. The biopharmaceutical company earned $2.56 million during the quarter, compared to analysts' expectations of $1.49 million. Achaogen had a negative net margin of 2,136.94% and a negative trailing twelve-month return on equity of 357.49%. What other stocks do shareholders of Achaogen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Achaogen investors own include Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Associated British Foods (ABF), Chaarat Gold (CGH), AMC Entertainment (AMC) and Ciena (CIEN). Company Calendar Last Earnings8/06/2018Today10/07/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:AKAO CIK1301501 Webwww.achaogen.com Phone650-800-3636FaxN/AEmployees206Year FoundedN/AProfitability EPS (Trailing Twelve Months)($3.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$186.51 million Net Margins-2,136.94% Pretax MarginN/A Return on Equity-357.49% Return on Assets-127.68% Debt Debt-to-Equity Ratio1.00 Current Ratio0.78 Quick Ratio0.77 Sales & Book Value Annual Sales$8.73 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.13) per share Price / BookN/AMiscellaneous Outstanding Shares63,880,000Free FloatN/AMarket Cap$7.03 million OptionableOptionable Beta0.78 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:AKAO) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achaogen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Achaogen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.